A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903.
ESMO Open. 2021 Jun;6(3):100115. doi: 10.1016/j.esmoop.2021.100115. Epub 2021 May 10.
ESMO Open. 2021.
PMID: 33984681
Free PMC article.